This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Pelago Bioscience acquires RG Discovery
Business acquisition

Pelago Bioscience acquires RG Discovery

Analysis based on 6 articles · First reported Jun 15, 2026 · Last updated Jun 15, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition of RG Discovery by Altor BioScience is expected to create a more integrated drug discovery platform, potentially accelerating drug development for biotechnology and pharmaceutical companies. This could lead to increased efficiency and faster time-to-market for new drugs, positively impacting the broader pharmaceutical industry.

Biotechnology Pharmaceuticals Contract Research
Event Summary

Altor BioScience, a drug discovery focused contract research organization (CRO) specializing in target engagement assays, announced the acquisition of RG Discovery. This strategic move integrates RG Discovery's expertise in medicinal chemistry, custom synthesis, and integrated drug discovery with Altor BioScience's biology-focused capabilities. The combined entity aims to offer a comprehensive platform for drug discovery, streamlining workflows and accelerating programs from hit identification through lead optimization. Michael Dabrowski, CEO of Altor BioScience, highlighted the importance of seamless integration between chemistry and biology, while Johan Evenas, CEO and Co-founder of RG Discovery, expressed enthusiasm for the expanded impact of their combined expertise. RG Discovery, founded in 2011 by former AstraZeneca scientists, employs approximately 40 scientists and operates from Lund, Sweden.

Entities Involved
oth
RG Discovery
RG Discovery was acquired by Altor BioScience, allowing it to integrate its chemistry expertise with Altor BioScience's biology-focused platform, enhancing its impact in drug discovery.
Importance 90.0 Sentiment 60.0
per
Michael Dabrowski
Michael Dabrowski, CEO of Altor BioScience, led the acquisition of RG Discovery, emphasizing the strategic importance of integrating chemistry and biology in drug discovery.
Importance 70.0 Sentiment 60.0
per
Johan Evenas
Johan Evenas, CEO and Co-founder of RG Discovery, expressed excitement about joining forces with Altor BioScience, highlighting the expanded impact of combining their expertise.
Importance 60.0 Sentiment 60.0
priv
Altor BioScience
Importance 0 Sentiment 0
stock
AstraZeneca
Importance 0 Sentiment 0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.